Outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections in intensive care units and prognostic effect of different antimicrobial regimens
Authors' conclusion
CRAB-BSIs are associated with high mortality in critically ill patients. In settings where novel antibiotics are not available, colistin-based therapy was associated with improved clinical outcomes. Among patients with pneumonia-related CRAB-BSIs, sulbactam-based therapy was associated with lower mortality.
Study context
- Population
- Critically ill ICU patients with carbapenem-resistant Acinetobacter baumannii bloodstream infections (BSIs), 5 medical centres in Taiwan, 2015–2019
- Participants
- 393 patients · 5 centres
- Exposure
- Antimicrobial regimens for Carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections
- Outcome
- Mortality
- Follow-up
- Day 28
Methodological detailsmulticentre, observational
- Multicentre
- Observational
Main finding
As reported in the abstract
Day-28 mortality
Colistin-basedAdjusted hazard ratio (95% CI)
Original cohort
0.56(0.35–0.88)
Time-window bias-adjusted cohort
0.59(0.37–0.94)
- Overall day-28 mortality rate following BSI onset
- 56.5%
Observational data: associations, not effects.
Further findings
Day-28 mortality, pneumonia-related CRAB-BSIs (subgroup)
| aHR for day-28 mortality (95% CI) | ||
|---|---|---|
| Sulbactam-based therapySurvival benefit | 0.37 (0.15–0.91) | |
| 0.10.31310AHR for day-28 mortality (log scale) |
- Colistin-based therapy did not significantly improve day-28 survival in this subgroup
Day-28 mortality, carbapenem-based and tigecycline-based therapy
- Neither carbapenem-based nor tigecycline-based therapy showed a mortality benefit
Original publication
Outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections in intensive care units and prognostic effect of different antimicrobial regimens. Ann Intensive Care. Published 18 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →